<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265900</url>
  </required_header>
  <id_info>
    <org_study_id>H14-02200</org_study_id>
    <nct_id>NCT02265900</nct_id>
  </id_info>
  <brief_title>Parkinson's Disease Exercise TMS PET Study</brief_title>
  <official_title>Exercise and Parkinson's Disease: The Basis for Motor and Cognitive Benefits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacific Parkinson's Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacific Parkinson's Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The therapeutic effects of exercise in Parkinson's disease (PD) are commonly reported,&#xD;
      however the mechanisms are unknown. The purpose of this study is to investigate the potential&#xD;
      mechanisms of exercise in the brain for the treatment of PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Positron Emission Tomography will be used to measure dopamine neuron density, endogenous&#xD;
      dopamine release and neuroimflammation. We will also use functional magnetic resonance&#xD;
      imaging (fMRI) to measure brain activity. Assessments will be conducted before and after a&#xD;
      12-week exercise intervention and 3-year follow-up. Participants will be randomly allocated&#xD;
      into either an aerobic or a stretching intervention. Clinical measures of motor function,&#xD;
      cognition and mood will also be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Covid Restrictions have impacted longitudinal assessments for the effect of the intervention&#xD;
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Dopamine release measured by RAC PET</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Exercise 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One type of exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A different type of exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>One type of exercise</description>
    <arm_group_label>Exercise 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>A different type of exercise</description>
    <arm_group_label>Exercise 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Diagnosed with Parkinson's Disease, Exercise less than 3x per week.&#xD;
&#xD;
        Exclusion Criteria. Describe which potential participants will be excluded from&#xD;
        participation, and list the criteria for their exclusion.&#xD;
&#xD;
          1. atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy,&#xD;
             drug-induced etc.);&#xD;
&#xD;
          2. significant osteoporosis or arthritis;&#xD;
&#xD;
          3. other neurological disease/complications (e.g. myopathy, stroke, brain lesion, MS);&#xD;
&#xD;
          4. self-reports claustrophobia;&#xD;
&#xD;
          5. history of cancer within 5 years of study participation;&#xD;
&#xD;
          6. high dose of radiation from other procedures within the year;&#xD;
&#xD;
          7. not able to tolerate being off PD medication for up to 24 hours;&#xD;
&#xD;
          8. a female subject who is breast-feeding or pregnant.&#xD;
&#xD;
          9. Subjects who regularly use anti-inflammatories (only excluded for PBR scans).&#xD;
&#xD;
        Exclusion criteria for MRI scanning and magnetic stimulation from repetitive Transcranial&#xD;
        Magnetic Stimulation (rTMS) scanning includes:&#xD;
&#xD;
          1. artificial heart valve;&#xD;
&#xD;
          2. brain aneurysm clip;&#xD;
&#xD;
          3. electrical stimulator for nerves or bones;&#xD;
&#xD;
          4. ear or eye implant;&#xD;
&#xD;
          5. implanted drug infusion pump;&#xD;
&#xD;
          6. coil, catheter, or filter in any blood vessel;&#xD;
&#xD;
          7. orthopedic hardware (artificial joint, plate, screws);&#xD;
&#xD;
          8. other metallic prostheses;&#xD;
&#xD;
          9. shrapnel, bullets, or other metal fragments;&#xD;
&#xD;
         10. surgery or tattoos (including tattooed eyeliner) in the last six weeks;&#xD;
&#xD;
         11. brain surgery&#xD;
&#xD;
         12. have a cardiac pacemaker, wires or defibrillator;&#xD;
&#xD;
         13. have had an injury where a piece of metal lodged in the eye or orbit;&#xD;
&#xD;
         14. have a ferromagnetic aneurysm clip; and&#xD;
&#xD;
         15. have a history of seizures/epilepsy&#xD;
&#xD;
         16. history of severe or uncontrolled headaches/migraines&#xD;
&#xD;
         17. taking medications that lower seizure threshold (e.g. amitryptiline, haloperidol)&#xD;
&#xD;
        Subjects may be excluded following study enrollment if they meet any of the following&#xD;
        exclusion criteria:&#xD;
&#xD;
          1. significant cognitive impairment or depression;&#xD;
&#xD;
          2. significant or unstable cardiovascular or respiratory disease - all subjects will&#xD;
             undergo a screening exercise bicycle stress test; or&#xD;
&#xD;
          3. failure to comply with the exercise or stretching intervention program by not&#xD;
             completing at least 30 of the 36 exercise classes.&#xD;
&#xD;
          4. Severe/multiple head trauma(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.J. Stoessl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Parkinson's Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Parkinson's Research Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 11, 2014</study_first_submitted>
  <study_first_submitted_qc>October 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pacific Parkinson's Research Centre</investigator_affiliation>
    <investigator_full_name>A. Jon Stoessl</investigator_full_name>
    <investigator_title>Director of Clinical PET</investigator_title>
  </responsible_party>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Parkinson's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

